Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will engage in a fireside chat on Thursday, September 5, 2024, from 3:45-4:20 pm ET.
Investors and interested parties can access a live webcast of the fireside chat through the Investor Relations section of Inozyme's website. A replay of the event will also be available for a time after the conference. This participation provides an opportunity for Inozyme to showcase its innovative therapeutics and engage with the investment community.
Inozyme Pharma (Nasdaq: INZY), un'azienda biofarmaceutica in fase clinica focalizzata su malattie rare che influenzano la salute delle ossa e la funzionalità dei vasi sanguigni, ha annunciato la sua partecipazione al 2024 Wells Fargo Healthcare Conference. Matt Winton, Ph.D., Vice Presidente Senior e Direttore Operativo di Inozyme, parteciperà a un incontro informale giovedì 5 settembre 2024, dalle 15:45 alle 16:20 ET.
Investitori e parti interessate possono accedere a un webcast dal vivo dell’incontro attraverso la sezione Relazioni con gli Investitori del sito web di Inozyme. Sarà disponibile anche una registrazione dell'evento per un certo periodo dopo la conferenza. Questa partecipazione offre a Inozyme l'opportunità di mettere in mostra le sue terapie innovative e interagire con la comunità degli investitori.
Inozyme Pharma (Nasdaq: INZY), una empresa biofarmacéutica en etapa clínica centrada en enfermedades raras que afectan la salud ósea y la función de los vasos sanguíneos, ha anunciado su participación en la 2024 Wells Fargo Healthcare Conference. Matt Winton, Ph.D., Vicepresidente Senior y Director de Operaciones de Inozyme, participará en una charla junto a la chimenea el jueves 5 de septiembre de 2024, de 3:45 a 4:20 p. m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la charla a través de la sección de Relaciones con Inversores en el sitio web de Inozyme. También estará disponible una repetición del evento por un tiempo después de la conferencia. Esta participación brinda a Inozyme la oportunidad de presentar sus terapias innovadoras e interactuar con la comunidad inversora.
Inozyme Pharma (Nasdaq: INZY)는 골 건강과 혈관 기능에 영향을 미치는 희귀 질환에 초점을 맞춘 임상 단계의 바이오 제약 회사로, 2024 웰스 파고 헬스케어 회의에 참여한다고 발표했습니다. Matt Winton, Ph.D., Inozyme의 부사장 겸 최고 운영 책임자는 2024년 9월 5일 목요일 오후 3시 45분부터 4시 20분까지 ET에 편안한 대화에 참여할 예정입니다.
투자자 및 관련자는 Inozyme 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 회의 후 일정 기간 동안 이벤트의 다시 보기를 제공할 것 입니다. 이번 참여는 Inozyme가 혁신적인 치료제를 선보이고 투자 커뮤니티와 소통할 수 있는 기회를 제공합니다.
Inozyme Pharma (Nasdaq: INZY), une entreprise biopharmaceutique en phase clinique axée sur les maladies rares affectant la santé osseuse et la fonction des vaisseaux sanguins, a annoncé sa participation à la 2024 Wells Fargo Healthcare Conference. Matt Winton, Ph.D., Vice-Président Senior et Directeur des Opérations d'Inozyme, participera à un échange informel jeudi 5 septembre 2024, de 15h45 à 16h20 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de l'échange via la section Relations Investisseurs du site Web d'Inozyme. Un enregistrement de l'événement sera également disponible pendant un certain temps après la conférence. Cette participation offre à Inozyme l'opportunité de présenter ses thérapies innovantes et d'interagir avec la communauté des investisseurs.
Inozyme Pharma (Nasdaq: INZY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten konzentriert, die die Knochengesundheit und die Funktion der Blutgefäße beeinträchtigen, hat seine Teilnahme an der 2024 Wells Fargo Healthcare Conference angekündigt. Matt Winton, Ph.D., Senior Vice President und Chief Operating Officer von Inozyme, wird an einem informellen Gespräch am Donnerstag, den 5. September 2024, von 15:45 bis 16:20 Uhr ET teilnehmen.
Anleger und Interessierte können über den Bereich Investor Relations auf der Website von Inozyme auf ein Live-Streaming des Gesprächs zugreifen. Eine Wiederholung der Veranstaltung wird auch für eine gewisse Zeit nach der Konferenz verfügbar sein. Diese Teilnahme bietet Inozyme die Möglichkeit, seine innovativen Therapien zu präsentieren und mit der Investmentgemeinschaft in Kontakt zu treten.
- None.
- None.
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 from 3:45-4:20 pm ET.
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com
FAQ
When is Inozyme Pharma (INZY) participating in the 2024 Wells Fargo Healthcare Conference?
Who will represent Inozyme Pharma (INZY) at the 2024 Wells Fargo Healthcare Conference?
How can investors access Inozyme Pharma's (INZY) presentation at the 2024 Wells Fargo Healthcare Conference?
What is the focus of Inozyme Pharma's (INZY) research and development?
